Related Experiment Video

Updated: Oct 5, 2025

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Stable Rates of Obstructive Hypertrophic Cardiomyopathy in a Contemporary Era

Michael Butzner1, Douglas L Leslie1, Yendelela Cuffee1,2

  • 1Department of Public Health Sciences, Pennsylvania State College of Medicine, Hershey, PA, United States.

Frontiers in Cardiovascular Medicine
|January 24, 2022
PubMed

Insights

Obstructive hypertrophic cardiomyopathy (oHCM) affects 1.65 per 10,000 individuals in the US. Most privately insured oHCM patients remain undiagnosed, highlighting a need for improved clinical identification.

Area of Science:

  • Cardiology
  • Genetics
  • Epidemiology

Background:

  • Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic heart disease in the US.
  • The clinical recognition of obstructive hypertrophic cardiomyopathy (oHCM) remains poorly understood.

Purpose of the Study:

  • To estimate the annual prevalence of clinically diagnosed oHCM in the US between 2016 and 2018.
  • To identify demographic disparities in oHCM diagnosis.

Main Methods:

  • Utilized the MarketScan® database from 2016-2018.
  • Identified patients with International Statistical Classification of Disease and Related Health Problems code I42.1 (oHCM).
  • Calculated and stratified oHCM prevalence by sex and age.

Main Results:

  • In 2016, oHCM prevalence was 1.65 per 10,000, with higher rates in males (2.07) than females (1.26).
  • Prevalence increased with age, peaking in the 55-64 age group (4.82 per 10,000).
  • Prevalence remained stable from 2016-2018 across demographic groups.

Conclusions:

  • The study indicates a significant underdiagnosis of oHCM among privately insured individuals in the US.
  • Findings underscore the necessity for enhanced clinical identification strategies and further research into oHCM.

Keywords:
ageclaims datahypertrophic cardiomyopathyobstructive hypertrophic cardiomyopathyprevalencesex

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.8K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.2K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
80
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
57
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
103
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
52
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
80
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
92